Baseline prevalence | Incidence over 2 years | |||||
---|---|---|---|---|---|---|
No | TPHA +ve | TPHA +ve RPR +ve | TPHA +ve RPR ≥1:8 | No* | TPHA +ve | |
*Number seen at follow up and TPHA negative at baseline. | ||||||
Males | ||||||
15–19 years | 1043 | 33 (3.2%) | 21 (2.0%) | 17 (1.6%) | 694 | 33 (4.8%) |
20–24 years | 1053 | 125 (11.9%) | 84 (8.0%) | 76 (7.2%) | 638 | 28 (4.4%) |
25–34 years | 1817 | 303 (16.7%) | 165 (9.1%) | 129 (7.1%) | 999 | 45 (4.5%) |
35–44 years | 1065 | 223 (20.9%) | 116 (10.9%) | 77 (7.2%) | 620 | 20 (3.2%) |
45–54 years | 978 | 173 (17.7%) | 70 (7.2%) | 45 (4.6%) | 634 | 22 (3.5%) |
Total | 5956 | 857 (14.4%) | 456 (7.7%) | 344 (5.8%) | 3585 | 148 (4.1%) |
Females | ||||||
15–19 years | 1175 | 103 (8.8%) | 78 (6.6%) | 68 (5.8%) | 647 | 44 (6.8%) |
20–24 years | 1365 | 207 (15.2%) | 144 (10.5%) | 104 (7.6%) | 767 | 21 (2.7%) |
25–34 years | 1968 | 375 (19.1%) | 215 (10.9%) | 147 (7.5%) | 1092 | 20 (1.8%) |
35–44 years | 1174 | 228 (19.4%) | 99 (8.4%) | 65 (5.5%) | 735 | 17 (2.3%) |
45–54 years | 948 | 157 (16.6%) | 69 (7.3%) | 43 (4.5%) | 596 | 16 (2.7%) |
Total | 6630 | 1070 (16.1%) | 605 (9.1%) | 427 (6.4%) | 3837 | 118 (3.1%) |